Weight-Loss

Obesity drug war may be about more than marketing to the overweight

Obesity drug war may be about more than marketing to the overweight

By

Category news shows that marketing to the obese may mean marketing to related conditions.

Takeda's Contrave hits pharmacy shelves

Takeda's Contrave hits pharmacy shelves

By

Takeda and Orexigen's prescription weight-loss drug Contrave has hit the market with a wraparound patient support system.

Takeda backs Contrave with 900 sales reps

Takeda backs Contrave with 900 sales reps

By

Takeda's Director of Obesity Marketing Katie Andino told MM&M in a phone interview that the drugmaker will be taking a unique approach to woo patients, physicians and payers.

CDC: Every state has an obesity problem

The latest data shows an overall widening of the US.

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

J&J, Vivus patent suit ends

J&J subsidiary Janssen has abandoned its patent lawsuit over the anti-seizure medication topiramate, which is part of Vivus's prescription weight-loss drug Qsymia.

Expanding weightloss drug doesn't wow

An experimental Gelesis weight-loss drug seeks the middle ground between surgery and appetite suppressants.

Dr. Oz runs afoul of lawmakers

Lawmakers criticized Columbia University chairman and professor of surgery Dr. Mehmet Oz for calling weight-loss supplements miracles on his TV program, despite lacking scientific proof to support those claims.

OPDP says phentermine site thin on details

OPDP says phentermine site thin on details

By

The bad-ad watchdog says the promotional website for the weight-loss medication Suprenza leaves out too much information.

FDA pauses Orexigen drug approval

FDA pauses Orexigen drug approval

By

The regulator wants more time to discuss post-marketing requirements.

Two more obesity meds circle Rx status

Gelesis is pouring money into its obesity "smart pill," and Novo reports weighty success among subjects taking liraglutide.

Weight-loss drugs fight it out

Eisai announced it was adding sales reps to promote its drug Belviq, while Vivus, maker of Qsymia, fights off a generic marketing application by Actavis.

Belviq partners up with phentermine

Arena and Eisai are testing Belviq with appetite suppressant phentermine.

Tot obesity drops, market ceiling still high

Tot obesity drops, market ceiling still high

By

A national survey indicates that obesity rates for children ages 2 to 5 has fallen since the early 2000s, yet overall numbers remain largely unchanged and high.

Weight-loss drugs plateau and expand

Weight-loss drugs plateau and expand

By

Analyst Thomas Wei reviews the prescription slimming category and sees two different realities for Vivus and Arena.

Orexigen could enter weight-loss race June 2014

Orexigen could enter weight-loss race June 2014

By

The drugmaker says interim trial data meets FDA review requirements and is hoping for June 2014 approval.

Eisai fills out Belviq consumer outreach

Eisai fills out Belviq consumer outreach

By

The marketing push follows the September launch of a patient support program and the announcement it was doubling its sales force.

Analyst: Eisai should hire more Belviq reps

Analyst: Eisai should hire more Belviq reps

By

A Credit Suisse analyst notes that the company will need to make a significant impact to meet even lowered expectations. A possible fix: more sales reps behind Belviq.

Business briefs: Bristol-Myers Squibb, Zafgen, GSK, Shire

Australia's price watchdogs are assessing the value of BMS cancer drug Yervoy; why a Phase II weight drug from Zafgen could open up the category; GSK halts a Crohn's trial; and Shire extends Santaris rare-disease collaboration

Business briefs: Eisai, Merck, plus another ACA delay

Eisai lobbies to push back Belviq's patent clock; a case against Paula Deen is dismissed; Merck and Avanir team up to promote Januvia; and another healthcare-reform measure is pushed back

Business briefs: GSK, Vivus, Biogen Idec, Astellas, Myriad

GSK says change is afoot in China; Vivus fight reportedly results in a new CEO; Biogen Idec enters a collaboration in Edinburgh; Astellas wins and FDA approval; Myriad's patent fight continues

Analysts on Qsymia: show me the payers

By

Analysts write expanded Qsymia distribution will do little to boost sales if payers are not on board.

Hyperbolic OTC obesity drug ads backfire

By

When it comes to OTC weight-loss products, deceptive advertising produces diminishing returns, a study has found.

Vivus launches Qsymia weight-loss app

By

The drug maker is promoting the no-fee, all-access app to healthcare professionals as part of its Qsymia pitch.

Orexigen rethinks clinical trial recruitment

By

Orexigen slashed its clinical trial recruitment period by 14 months using marketing tactics associated with retail.

Weight-loss category enters 2013 light on results

By

The category that saw its first FDA-approved drug in 13 years is still waiting to take off.

Company news: Burson-Marsteller, Corcept and Orexigen

PR firm Burson-Marsteller launched a new healthcare subsidiary, Orexigen's net loss widened in Q2, and Corcept closed out its first full quarter with orphan treatment Korlym.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters